...
....
Pharmaceutical
Biotechnology

> See specialized channels
Medical Devices & Diagnostics
> See specialized channels
Industrial
Biotechnology
> See specialized channels


  Join us

  Follow us on Twitter   Join our LinkedIn Group   Our Blog

Biotech News App
Provides access to the latest biotech press releases ...more

Android_Logo App Store RIM_Logo_small

Media Partnership:
Want to have your RSS feed integrated on our website? Contact us
RSS Feeds RSS Feeds
JoomlaWatch Stats 1.2.9 by Matej Koval
For Editors
Sign up for press releases
For Companies
Sign up for our newsletter
Back to PRESS RELEASES - 

Vectron Biosolutions Obtains Strong Results for Biosimilar Production

| Print |
Friday, 10 February 2012 10:45 (UTC + 1)

vectron_logo

Trondheim, Norway, February 10, 2012 / B3C newswire / - Vectron Biosolutions announced today that they have obtained strong results for manufacture of selected biosimilar proteins using their proprietary E. coli expression technology. The study was done side-by-side with other expression technologies and Vectron’s technology gave higher soluble and/or insoluble yields for seven out of 10 tested biosimilar proteins. The increase in yield was 2 to 25 times compared to the best conventional technology.

The biosimilar proteins that were produced more efficiently with Vectron’s technology than with other technologies were human growth hormone, interferon β-1b, TNF α-1a, IGF-1, insulin, IL-2, and IL-1RA.

“Demonstrating that our technology is superior for manufacture of many valuable therapeutic proteins is a major milestone for us,” commented CEO in Vectron Biosolutions AS, Trond Erik Vee Aune. “Significant increases in soluble and insoluble yields translate directly to large savings in cost of goods for our pharmaceutical partners, especially in the highly competitive biosimilars market where cost-efficient manufacturing processes are essential. In addition, demonstrating that our technology can be used to obtain many-fold higher titers means that our services and technology is highly suitable for new therapeutic proteins being developed, especially those where low solubility and/or low yields are a complicating issue.”


About
Vectron Biosolutions AS
Through a combination of experienced life science researchers, state-of-the-art laboratory facilities, a proprietary technology platform and competent management, Vectron Biosolutions AS supplies the pharmaceutical industry with state-of-the-art technology and solutions for manufacture of recombinant proteins in E. coli and other bacteria.


Contact
Dr. Trond Erik Vee Aune, CEO
Vectron Biosolutions AS
Phone: +47 95027449
This e-mail address is being protected from spambots. You need JavaScript enabled to view it